纤维蛋白粘合剂作为抗肿瘤等药物缓释载体的研究进展  

Research Progress on the Fibrin Sealant as Sustained-release Carrier for Antitumor and other Drugs

作　　者：夏占强 张华[2] 易喻[2] 应国清[2] 

机构地区：[1]浙江海正药业有限公司,浙江杭州311118 [2]浙江工业大学药学院,浙江杭州310014

出　　处：《肿瘤药学》2012年第4期253-256,共4页Anti-Tumor Pharmacy

摘　　要：纤维蛋白粘合剂作为药物缓释载体因其具有良好的缓释性、生物相容性和定向作用,已被广泛应用于临床;其可通过模拟机体凝血过程的最后阶段,形成海绵状纤维蛋白凝胶,凝胶呈三维结构的纤维蛋白多聚体,和抗肿瘤等药物联合使用时可以将药物包合在凝胶内,形成储药库,当喷射或涂布于创面后,随着凝胶被逐渐吸收和降解,药物被缓慢释放,产生理想的定向缓释作用。此作用机制特别适合局部肿瘤治疗、抗菌治疗及局麻镇痛药物等方面的联合使用;在减少给药次数,降低药物毒副作用,提高药物治疗效果等方面具有非常好的应用前景。近年来,纤维蛋白粘合剂的缓释作用越来越受到学者们的重视,成为研究的热点。本文将对纤维蛋白粘合剂联合抗肿瘤等药物形成缓释体系的机理及临床应用进行综述。As the drug delivery carrier, fibrin sealant has been widely applied in clinic for its good slow-releasing effect, biocompatibility, and orientation interaction. By simulating the last phase of the coagulation process of human body, fibrin sealant can form the cavernous fibrin gel, which appears as fibrin polymer in a three-dimensional structure. When combined with the antitumor drugs, it can package the drug into the gel and form the drug storage. After injected or coated on the wound, along with the uptake and degradation of the gel, the drugs are slowly released, achieving the desired orientated slow-releasing effect. This mechanism is especially suitable for the combined use of local tumor therapy, antibiotic treatment and local anesthesia analgesia drugs. It has a wide application prospect in aspects of reducing dosing frequency, decreasing toxic or side effects, and improving the clinical efficacy. The slow-releasing effect of fibrin sealant has recently become more and more popular and proved to be the research hot spot. This paper reviewed the slow-releasing system mechanism and clinical application of fibrin sealant in combined use with antitumor and other drugs.

关 键 词：纤维蛋白粘合剂 药物 缓释 载体 

分 类 号：R730.1[医药卫生—肿瘤] R944.15[医药卫生—临床医学]